Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34


Cellular Immunotherapy of Canine Cancer.

Addissie S, Klingemann H.

Vet Sci. 2018 Dec 6;5(4). pii: E100. doi: 10.3390/vetsci5040100. Review.


Immunotherapy for Dogs: Running Behind Humans.

Klingemann H.

Front Immunol. 2018 Feb 5;9:133. doi: 10.3389/fimmu.2018.00133. eCollection 2018. Review.


Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.

Oelsner S, Friede ME, Zhang C, Wagner J, Badura S, Bader P, Ullrich E, Ottmann OG, Klingemann H, Tonn T, Wels WS.

Cytotherapy. 2017 Feb;19(2):235-249. doi: 10.1016/j.jcyt.2016.10.009. Epub 2016 Nov 22.


An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele.

Jochems C, Hodge JW, Fantini M, Fujii R, Morillon YM 2nd, Greiner JW, Padget MR, Tritsch SR, Tsang KY, Campbell KS, Klingemann H, Boissel L, Rabizadeh S, Soon-Shiong P, Schlom J.

Oncotarget. 2016 Dec 27;7(52):86359-86373. doi: 10.18632/oncotarget.13411.


Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK Cells.

Klingemann H, Boissel L, Toneguzzo F.

Front Immunol. 2016 Mar 14;7:91. doi: 10.3389/fimmu.2016.00091. eCollection 2016. Review.


CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies.

Romanski A, Uherek C, Bug G, Seifried E, Klingemann H, Wels WS, Ottmann OG, Tonn T.

J Cell Mol Med. 2016 Jul;20(7):1287-94. doi: 10.1111/jcmm.12810. Epub 2016 Mar 23.


NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy.

Suck G, Odendahl M, Nowakowska P, Seidl C, Wels WS, Klingemann HG, Tonn T.

Cancer Immunol Immunother. 2016 Apr;65(4):485-92. doi: 10.1007/s00262-015-1761-x. Epub 2015 Nov 11. Review.


Challenges of cancer therapy with natural killer cells.

Klingemann H.

Cytotherapy. 2015 Mar;17(3):245-9. doi: 10.1016/j.jcyt.2014.09.007. Epub 2014 Dec 18. Review.


Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.

Schönfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, Nowakowska P, Bönig H, Köhl U, Kloess S, Köhler S, Holtgreve-Grez H, Jauch A, Schmidt M, Schubert R, Kühlcke K, Seifried E, Klingemann HG, Rieger MA, Tonn T, Grez M, Wels WS.

Mol Ther. 2015 Feb;23(2):330-8. doi: 10.1038/mt.2014.219. Epub 2014 Nov 6.


Are natural killer cells superior CAR drivers?

Klingemann H.

Oncoimmunology. 2014 Apr 15;3:e28147. eCollection 2014.


Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity.

Boissel L, Betancur-Boissel M, Lu W, Krause DS, Van Etten RA, Wels WS, Klingemann H.

Oncoimmunology. 2013 Oct 1;2(10):e26527. Epub 2013 Oct 22.


Treatment of patients with advanced cancer with the natural killer cell line NK-92.

Tonn T, Schwabe D, Klingemann HG, Becker S, Esser R, Koehl U, Suttorp M, Seifried E, Ottmann OG, Bug G.

Cytotherapy. 2013 Dec;15(12):1563-70. doi: 10.1016/j.jcyt.2013.06.017. Epub 2013 Oct 1.


Cellular therapy of cancer with natural killer cells-where do we stand?

Klingemann HG.

Cytotherapy. 2013 Oct;15(10):1185-94. doi: 10.1016/j.jcyt.2013.03.011. Epub 2013 Jun 13. Review.


Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions.

Klingemann H, Grodman C, Cutler E, Duque M, Kadidlo D, Klein AK, Sprague KA, Miller KB, Comenzo RL, Kewalramani T, Yu N, Van Etten RA, McKenna DH.

Transfusion. 2013 Feb;53(2):412-8; quiz 411. doi: 10.1111/j.1537-2995.2012.03764.x. Epub 2012 Jun 28.


Successful "in-flight" activation of natural killer cells during long-distance shipping.

Koepsell SA, Kadidlo DM, Fautsch S, McCullough J, Klingemann H, Wagner JE, Miller JS, McKenna DH Jr.

Transfusion. 2013 Feb;53(2):398-403. doi: 10.1111/j.1537-2995.2012.03695.x. Epub 2012 May 11.


Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model.

Lu YF, Gavrilescu LC, Betancur M, Lazarides K, Klingemann H, Van Etten RA.

Blood. 2012 Jan 5;119(1):273-84. doi: 10.1182/blood-2011-01-331009. Epub 2011 Nov 9.


Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens.

Boissel L, Betancur M, Lu W, Wels WS, Marino T, Van Etten RA, Klingemann H.

Leuk Lymphoma. 2012 May;53(5):958-65. doi: 10.3109/10428194.2011.634048. Epub 2011 Dec 6.


Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial.

Marty FM, Ljungman P, Papanicolaou GA, Winston DJ, Chemaly RF, Strasfeld L, Young JA, Rodriguez T, Maertens J, Schmitt M, Einsele H, Ferrant A, Lipton JH, Villano SA, Chen H, Boeckh M; Maribavir 1263-300 Clinical Study Group.

Lancet Infect Dis. 2011 Apr;11(4):284-92. doi: 10.1016/S1473-3099(11)70024-X. Epub 2011 Mar 21. Erratum in: Lancet Infect Dis. 2011 May;11(5):343.


Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia.

Weitzman J, Betancur M, Boissel L, Rabinowitz AP, Klein A, Klingemann H.

Leuk Lymphoma. 2009 Aug;50(8):1361-8. doi: 10.1080/10428190903026500.


Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells.

Boissel L, Betancur M, Wels WS, Tuncer H, Klingemann H.

Leuk Res. 2009 Sep;33(9):1255-9. doi: 10.1016/j.leukres.2008.11.024. Epub 2009 Jan 14.

Supplemental Content

Loading ...
Support Center